Binimetinib Brand Name– MEKTOVI
What is Binimetinib
Binimetinib is a MEK inhibitor that inhibits cell growth in BRAF V600 mutation-positive tumors.
Using an FDA-approved test, confirm the presence of the BRAF V600 mutation in tumor specimens prior to initiation of treatment.
Binimetinib is indicated in combination with encorafenib for the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma.
Cardiomyopathy, venous thromboembolism, interstitial lung disease, and rhabdomyolysis have been reported with binimetinib use.
Indications
- malignant melanoma
Side Effects
- abdominal pain
- anemia
- bleeding
- cardiomyopathy
- colitis
- constipation
- diarrhea
- dizziness
- elevated hepatic enzymes
- fatigue
- fever
- GI bleeding
- heart failure
- hypertension
- hyponatremia
- interstitial lung disease
- intracranial bleeding
- iritis
- leukopenia
- lymphopenia
- macular edema
- nausea
- nephrotoxicity
- neutropenia
- panniculitis
- peripheral edema
- pneumonitis
- pulmonary embolism
- rash
- retinal detachment
- retinopathy
- rhabdomyolysis
- thromboembolism
- thrombosis
- uveitis
- visual impairment
- vomiting
Monitoring Parameters
- creatine phosphokinase (CPK)
- echocardiogram
- ejection fraction
- LFTs
- multi-gated radionuclide angiography (MUGA)
- ophthalmologic exam
- pregnancy testing
- serum creatinine
Contraindications
- breast-feeding
- cardiomyopathy
- contraception requirements
- heart failure
- hepatic disease
- iritis
- pregnancy
- pregnancy testing
- reproductive risk
- retinal detachment
- rhabdomyolysis
- uveitis
- ventricular dysfunction
- visual disturbance
- visual impairment
Interactions
There are no drug interactions associated with Binimetinib products.
